A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804 · PHASE3 · RECRUITING · Sponsor: Eli Lilly and Company · Conditions: Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal
PR
By Priya Raman · Science Reporter
Nov 4 07:00 ETSource: ClinicalTrials.gov
From the source
Read at clinicaltrials.govA Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804 · PHASE3 · RECRUITING · Sponsor: Eli Lilly and Company · Conditions: Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms.
Source URL https://clinicaltrials.gov/study/NCT07213804
